Project Grant R13CA264976

Award Date 8/1/21

Completion Date 8/2/21

Dollars Obligated $3

Federal Agency

National Cancer Institute

Awardee

American Association For Cancer Research, Inc. (K4LZTWHBSGN6)

Federal Grant Program

93.396

Assistance Type

Project Grant

Place of Performance

Pennsylvania, USA

Similar Awards

Cooperative Agreement NU58DP007961
Summary of Federal Cooperative Agreement Award The Minnesota Department of Health received a $684,000 cooperative agreement award dated August 30, 2025, through the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). Under this five-year performance period (through August 29, 2030), the Minnesota Cancer Screening Quality Improvement (CSQI)...
Cooperative Agreement NU58DP007959
Summary The Alabama Department of Public Health received a $483,280 Cooperative Agreement award dated August 30, 2025, through the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). The Alabama Colorectal Cancer Program (ACRCP) will implement evidence-based interventions to increase colorectal cancer screening rates among at-risk Alabama...
Project Grant R21CA292205
Federal Project Grant Award Summary The National Cancer Institute awarded $394,532 through its Cancer Treatment Research program (CFDA 93.395) to the Regents of the University of Minnesota on July 15, 2025, to support research investigating LAT1 (L-type amino acid transporter 1) as a novel therapeutic target in colorectal cancer. The research will be conducted through June 30, 2027, and focuses on developing innovative treatment approaches for microsatellite stable (MSS) tumors, which...
Cooperative Agreement UG3CA301294
Summary Columbia University's Health Sciences Division received a $727,904 Cooperative Agreement award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 11, 2025, for research on engineered probiotic bacteria to prevent and intercept colorectal cancer (CRC). The award supports a two-phase UG3/UH3 project designed to develop and characterize engineered strains of Escherichia coli Nissle 1917 (ECN) that selectively colonize precancerous lesions...
Project Grant R21CA283138
This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...
Cooperative Agreement NU58DP007974
Summary of PROTECT-AR Cooperative Agreement Award The University of Arkansas for Medical Sciences (UAMS) Primary Care Population Health Service Line received a $1,633,260 cooperative agreement from the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion, effective August 30, 2025 through August 29, 2030, under the Organized Approaches to Increase Colorectal Cancer Screening program (CFDA 93.800). The PROTECT-AR initiative implements...
Project Grant R00CA297022
Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $248,998 Project Grant on September 16, 2025, to Massachusetts General Hospital to support research integrating multi-omics analysis with a medically tailored meal intervention targeting ultra-processed food (UPF) consumption for colorectal cancer (CRC) prevention and control. This award, funded under the Cancer Treatment Research program (CFDA 93.395), supports a K99/R00 career development grant combining investigator...
Project Grant R03CA304041
Federal Grant Award Summary The University of Cincinnati received a $162,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2027. This award funds research to develop and evaluate novel combination treatment strategies targeting colorectal cancer patients with KRAS mutations. The project specifically investigates the efficacy of combining KRAS inhibitors with HER3 (human epidermal...
Project Grant R01CA276430
The Project Grant award of $637,596.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop and test a video-based intervention to reduce defensive cancer information avoidance and increase the reach of colorectal cancer screening messaging. The intervention is designed to increase self-efficacy and positive affect among those who typically avoid colorectal cancer information, with the goal of improving screening rates. The project includes a...
Project Grant R21CA302991
Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $393,872 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025 through July 31, 2027. The award supports research and development of therapeutic antibody-drug conjugates (ADCs) targeting leucine-rich repeat containing G protein-coupled receptor 5 (LGR5) and the receptor tyrosine kinase MET to overcome tumor...

AACR SPECIAL CONFERENCE ON COLORECTAL CANCER - ABSTRACT THE PROPOSED CONFERENCE, ENTITLED "COLORECTAL CANCER" WILL BE HELD OCTOBER 21-24, 2021 IN MINNEAPOLIS, MINNESOTA. THIS WILL BE THE SECOND AACR CONFERENCE FOCUSED SPECIFICALLY ON ADVANCES IN COLORECTAL CANCER HELD IN THE LAST 5 YEARS. COLORECTAL CANCERS (CRC'S), ARE THE SECOND LEADING CAUSE OF CANCER DEATHS IN THE UNITED STATES. UNFAVORABLE RISK FACTORS SUCH AS OBESITY, PHYSICAL INACTIVITY, AND SMOKING IN ADDITION TO AN AGEING POPULATION AND DIETARY HABITS OF HIGH- INCOME COUNTRIES INCREASES THE RISK OF CRC. CRC INCIDENCE AND MORTALITY RATES ARE ALSO RISING IN THE YOUNG-ONSET POPULATION, WITH ~12% OF CASES BEING DIAGNOSED IN INDIVIDUALS UNDER AGE 50. ADVANCEMENTS IN PATHOPHYSIOLOGICAL UNDERSTANDING HAVE INCREASED THE ARRAY OF TREATMENT OPTIONS FOR LOCAL AND ADVANCED DISEASE LEADING TO INDIVIDUAL TREATMENT PLANS ALTHOUGH CURRENT THERAPIES HAVE LED TO AN OVERALL DECREASE IN CRC INCIDENCE AND MORTALITY, THE 5-YEAR SURVIVAL RATE FOR PATIENTS WITH ADVANCED METASTATIC CRC STANDS AT ABOUT 14%. CRC MORBIDITY AND MORTALITY CAN BE MITIGATED THROUGH APPROPRIATE SCREENING AND SURVEILLANCE HOWEVER ITS EFFECTIVENESS IS JEOPARDIZED BY A SEVERAL FACTORS INCLUDING THE LACK OF ACCESSIBILITY AND SUBOPTIMAL SCREENING COMPLIANCE. THESE DATA HIGHLIGHT THE ACUTE NEED FOR CONTINUED RESEARCH TO IMPROVE DIAGNOSTIC TESTING AND TREATMENT PARADIGMS. WITH THE AIM OF CONNECTING BASIC AND TRANSLATIONAL RESEARCH TO CLINICAL CARE, THE PROPOSED CONFERENCE WILL BRING TOGETHER RESEARCH SCIENTISTS AND CLINICIANS TO DISCUSS THE LATEST FINDINGS IN CRC RESEARCH. TO THIS END, THE AACR IS SEEKING SUPPORT TO EXPAND THE CONFERENCE AND TO RECRUIT OUTSTANDING YOUNG INVESTIGATORS THROUGH ADDITIONAL SCHOLAR-IN- TRAINING AWARDS. ATTENDANCE BY THIS "NEXT GENERATION" OF CANCER SCIENTISTS AND CAREGIVERS WILL HELP BETTER DISSEMINATE THE RAPIDLY GROWING COLLECTION OF RESEARCH INNOVATIONS AS WELL AS IGNITE NEW COLLABORATIONS. THE PROGRAM HAS BEEN CAREFULLY DESIGNED TO FEATURE THOUGHT-PROVOKING SESSIONS ON ADVANCES IN RISK FACTORS AND PREVENTION, GENOMICS, MICROBIOME, IMMUNOTHERAPY, AND OTHER EMERGING THERAPIES. COLLABORATION AND NETWORKING WILL ALSO BE ENCOURAGED BY INCORPORATING MULTIPLE OPPORTUNITIES FOR THOUGHTFUL DISCUSSION AND MEANINGFUL INTERACTION BETWEEN PARTICIPANTS.

Posted 6/23/21

Mod #	Federal Obligation	Date
Not listed	($1)	2/2/23
Not listed	$1	1/28/22
Not listed	$1	1/28/22
Not listed	$1	1/28/22
Not listed	($7k)	7/23/21